Plans are also underway to begin three additional Phase Ib expansion studies focusing on different combinations and patient ...

AstraZeneca has made the decision to end the CAPItello-280 trial evaluating capivasertib in patients with metastatic castration-resistant prostate cancer.

Janux Therapeutics Initiates Phase 1b Expansion Studies with JANX007 in Patients with Prostate Cancer and Provides Program ...

AstraZeneca is discontinuing the CAPItello-280 Phase III trial evaluating the efficacy and safety of Truqap (capivasertib) in combination with docetaxel and androgen-deprivation therapy (ADT) compared ...

The CAPItello-280 study (NCT05348577) was investigating Truqap in combination with docetaxel and androgen-deprivation therapy ...

VANCOUVER, Canada I April 29, 2025 I AbCellera (Nasdaq: ABCL) today announced new data on its PSMA x CD3 T-cell engagers (TCEs), presented as a poster at the ...

AstraZeneca has announced the discontinuation of the CAPItello-280 Phase III trial evaluating the efficacy and safety of ...

AstraZeneca to discontinue CAPItello-280 phase III trial of Truqap in metastatic castration-resistant prostate cancer: Cambridge, UK Wednesday, April 30, 2025, 10:00 Hrs [IST] Ast ...

Patients treated with darolutamide who reached ultra-low PSA at any time had lower risk of radiological progression or death versus those with PSA >=0.2 ng/mL, with a risk reduction of 91%, as did ...